Key Steps in Custom DNA Oligonucleotide Synthesis

What Is Custom DNA Oligonucleotide Synthesis? Custom DNA oligonucleotide synthesis is the chemical process of building short, single-stranded DNA sequences—called oligonucleotides or “oligos”—in a controlled, laboratory setting. These synthetic DNA molecules are indispensable tools in modern molecular biology, genomics, diagnostics, and therapeutic development. Whether you are designing primers for PCR amplification, probes for next-generation sequencing…

Bioserve – A REPROCELL Company Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…

Major Global News & Breakthroughs in Stem Cell Research

Stem cell research has entered a decisive translational era. Breakthroughs in induced pluripotent stem cell (iPSC) technology and precision gene editing are rapidly converting experimental concepts into clinically validated therapies. What were once proof-of-concept studies are now progressing through late-stage clinical trials and, in some cases, delivering first-in-human successes. These advances are unlocking new therapeutic frontiers…

Bioserve – A REPROCELL COMPANY Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System

January 28th, 2026 – REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL’s StemRNA™ Clinical…